DDMoRe launches new modelling languages
Leiden, the Netherlands, 20th December 2013 - The IMI Drug Disease Model
Resources http://www.ddmore.eu) consortium is launching modelling
languages to enable quantitative decision making across all stages of
pharmaceutical drug development. This first release includes a "universal"
Modelling Description Language http://www.ddmore.eu/mdl) together with
its Integrated Development Environment http://www.ddmore.eu/mdl-ide)
and a new exchange language standard, the Pharmacometrics Markup Language
http://www.ddmore.eu/pharmml). MDL and PharmML will be the backbone
of the forthcoming DDMoRe open-source model repository and interoperability
framework. DDMoRe envisages that the standards and tools developed over the
course of the project will facilitate future collaborative drug and disease
Modelling and Simulation (M&S) work.
MDL is a "universal" human orientated M&S language to describe models and
related tasks. MDL has been designed to be easily read and written by
scientists. The MDL is independent of the targeted modelling software and uses
discrete objects to separate data, parameter, model and task descriptions. This
supports re-usability and interchange of the objects defining the modelling
task. Analysis flexibility will be enhanced by allowing combinations of
existing modelling objects. These discrete objects will also facilitate use of
the forthcoming DDMoRe model repository.
The MDL-IDE provides the framework where the files containing MDL code can be
created and edited. It offers a user-friendly and customisable interface
including syntax highlighting, assistance in model/object formatting and
simultaneous development of multiple models. This release supports conversion
of MDL objects into the equivalent NM-TRAN control stream. To show this
functionality a set of use cases is provided, many of which produce NM-TRAN
code that is directly executable within NONMEM.
To enable the exchange and reuse of models/objects, annotations, and associated
tasks, DDMoRe has developed a mark-up language, the PharmML. This first release
supports non-linear mixed effect models as used in analysis and simulation of
continuous longitudinal population data. Future releases will support discrete
data models, Bayesian inference methods and delay differential equations.
User feedback request
MDL, MDL-IDE, and PharmML are under active development and these first releases
are intended to gather feedback from the broader user community outside the
DDMoRe consortium. Please provide feedback on your experiences and suggestions
for enhancements on http://www.ddmore.eu/forum.
About DDMoRe
The DDMoRe consortium is an IMI project, involving 26 partners (drawn from the
Pharmaceutical Industry, Academia and Small to Medium Enterprises) with the aim
of facilitating Model-Based Drug Development (MBDD) approaches via development
of a new M&S platform and model library. MBDD is widely accepted as a vital
approach in understanding patients' drug-related benefit and risk. However, the
current path to model-based knowledge integration is hampered by a lack of
common tools, languages and ontologies for M&S, with limited or time consuming
access to stored or evolving information. To address those concerns DDMoRe was
formed as a 5-years IMI project http://www.imi.europa.eu)
in 2011.
DDMoRe aims at qualifying, supporting and maintaining a streamlined platform
that is robust, auditable, flexible and scalable. DDMoRe encourages good data
analytical practice and promotes to simplify the re-use of previous work to
support timely quantitative decision making in drug development.
So far, key achievements include the release of MDL, MDL-IDE, and PharmML and
an encoding of published models in core therapeutic areas: diabetes, oncology,
CNS, infectious and inflammatory diseases. A first public instance of the
model repository will be theme of a next release note in Q1 2014.
For more information,
Lutz Harnisch Mats Karlsson
Wendy Aartsen
Coordinator Scientific Coordinator
Project Communication
E-mail: [email protected]<mailto:[email protected]>
The research leading to these results has received support from the Innovative
Medicines Initiative Joint Undertaking under grant agreement n° 115156,
resources of which are composed of financial contributions from the European
Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in
kind contribution. The DDMoRe project is also financially supported by
contributions from Academic and SME partners.
[cid:[email protected]]
[cid:[email protected]] [cid:[email protected]]
[cid:[email protected]]
<<inline: image001.jpg>>
<<inline: image002.jpg>>
<<inline: image003.jpg>>
<<inline: image004.jpg>>